Literature DB >> 2303581

The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers.

N Inotsume1, M Nishimura, M Nakano, S Fujiyama, T Sato.   

Abstract

Effects of coadministration of probenecid on pharmacokinetic behaviors of famotidine, an H2-receptor antagonist, after oral administration, were studied in eight young, healthy volunteers. They received an oral 20 mg dose of famotidine with and without coadministration of oral 1500 mg doses of probenecid. The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml. The mean urinary excretion rate of unchanged famotidine, the mean amount of unchanged famotidine excreted in urine up to 24 hours and mean renal clearance were decreased by coadministration of probenecid. The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min. These data suggest that probenecid, which is a classical inhibitor of renal tubular secretion of organic anions, inhibits the renal tubular secretion of famotidine, which exists partly in a cationic form under physiological pH conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303581     DOI: 10.1002/j.1552-4604.1990.tb03438.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

1.  Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration.

Authors:  S L Wong; M A Hedaya; R J Sawchuk
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

2.  The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.

Authors:  J W Massarella; L A Nazareno; S Passe; B Min
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 5.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

6.  Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney.

Authors:  Harunobu Tahara; Masayuki Shono; Hiroyuki Kusuhara; Hajime Kinoshita; Eiichi Fuse; Akira Takadate; Masaki Otagiri; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

7.  Probenecid interferes with renal oxidative metabolism: a potential pitfall in its use as an inhibitor of drug transport.

Authors:  R Masereeuw; A P van Pelt; S H van Os; P H Willems; P Smits; F G Russel
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

8.  Bisubstrates: substances that interact with renal contraluminal organic anion and organic cation transport systems. I. Amines, piperidines, piperazines, azepines, pyridines, quinolines, imidazoles, thiazoles, guanidines and hydrazines.

Authors:  K J Ullrich; G Rumrich; C David; G Fritzsch
Journal:  Pflugers Arch       Date:  1993-11       Impact factor: 3.657

Review 9.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

10.  Stereoselective renal tubular secretion of carbenicillin.

Authors:  T Itoh; M Ishida; Y Onuki; Y Tsuda; H Shimada; H Yamada
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.